Your Daily Money Briefing

Trump Called Off the Strike on Iran This Time. Oil Dropped 5% Before the Opening Bell.

Four things that actually moved money today. No fluff, no hedging, just what happened.

Trump Canceled a Planned Strike on Iran. Talks Resume Today.

Reports Friday said Trump was gearing up for a fresh wave of strikes as hopes for a deal faded. Sunday, he called it off — said he canceled the attack and that talks with Iran would restart today. Oil didn't wait around to celebrate quietly: Brent dropped 5.2% to $83.39, WTI fell 6.2% to $79.45. Futures followed, with the Dow up more than 400 points ahead of the open.

Duck it — we've called "peace" on this conflict before and been wrong within days. This time it's a canceled strike and a promise to talk, not a signed deal. Read the oil drop as relief that things didn't get worse, not proof they're actually fixed.

Watch what actually comes out of today's talks before adjusting anything based on a headline alone.

Korea's Market Just Gave Back Its Best Day on Record

Friday, the Kospi had its best single day ever recorded. Monday, it fell over 5%, handing back a chunk of that gain. Japan's Nikkei slipped almost 1%. This is the same chip-driven volatility we've been tracking for weeks — Korea's market has become the loudest, most emotional register on the whole AI trade.

If you're trading Korean chip names specifically, this level of daily swing is now just the environment you're operating in. Size positions like it.

The U.S. and Japan Just Stepped In to Prop Up the Yen — Together

Japan's Finance Ministry confirmed it conducted a coordinated yen-buying intervention with the United States, and the Treasury Department reportedly stepped in to support the yen directly. Both countries say they're ready to do it again. This isn't routine — governments don't jointly intervene in currency markets often, and when they do, it's usually because something's moving faster than they're comfortable with.

Duck it — a joint U.S.-Japan currency intervention is the kind of quiet story that doesn't trend but genuinely matters. If you hold anything with international or currency exposure, this is worth ten minutes of actual reading, not a skim.

AstraZeneca and Bristol Myers Are Reportedly Talking About a $400 Billion Deal

The Financial Times is reporting that AstraZeneca is in talks with Bristol Myers Squibb on a deal that could be worth $400 billion — one of the biggest potential pharmaceutical mergers ever discussed. Nothing's signed. But a number that size, even as a rumor, is enough to move both stocks and reshape how investors think about the entire pharma sector's next few years.

Deals this size take months to actually close, if they close at all. Don't chase either stock on the headline alone — but do start paying attention to this one.

This is a market news summary, not investment advice. Economic and financial conditions are subject to change — please make your own decisions and consider talking to a licensed financial advisor before acting on anything here.

© 2026 duckitnow.com · You're receiving this because you subscribed to our daily briefing. Unsubscribe